Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 May 2021 | Story Leonie Bolleurs | Photo Sonia Small
Prof Robert Bragg recently participated in a live panel discussion with leaders from the food and beverage sector, debating the challenges facing the industry and sharing their lessons and solutions.

Prof Robert Bragg from the Department of Microbiology and Biochemistry at the University of the Free State formed part of a live panel discussion with leaders from the food and beverage sector, debating the challenges facing the industry and sharing their lessons and solutions.

The discussion, part of a week-long virtual event (19-23 April), was attended by more than 1 300 attendees representing 500 food manufacturers, retailers, ingredient companies, and laboratories from 83 countries.

The magazine, New Food, coordinated the initiative that focused on food integrity. Speaking with Prof Bragg at the session that centred around animal welfare, zoonotic disease, and antibiotics, were Catherine McLaughlin, Chair, Responsible Use of Medicines in Agriculture (RUMA); Vicky Bond, UK Managing Director, The Humane League; and Daniela Battaglia, Livestock Development Officer, Food and Agriculture Organization of the United Nations (FAO).

The rise of antibiotic resistance

James Russell, President of the British Veterinary Association (BVA), was the moderator of the discussion that also touched on the issues surrounding animal welfare; how animal welfare can impact meat quality; avoiding future zoonotic disease; the rise of antibiotic resistance; ethical considerations to be mindful of; and the use of pesticides and safety considerations.

Prof Bragg specifically talked about antibiotic resistance. “Mankind has major problems with antibiotics,” he said. 

He asked if animal agriculture can be sustained without the use of antibiotics and stated that it was necessary to look at alternatives. Possible solutions he suggested include improved vaccines, bacteriophages, and phage enzymes. He, however, believes that biosecurity will be the most effective alternative. 

Living in a post-antibiotic area

Disinfectants are one of the biosecurity measures taken to minimise the risk of infectious diseases. “But it is important to be aware of the fact that as resistance to antibiotics increases the resistance to disinfectants also increases,” said Prof Bragg. 

He continued: “An increase in the use of disinfectants increases the resistance to disinfectants. This is also evident in humans, especially now during the COVID-19 pandemic. Much of these disinfectants are also of poor quality,” he said. 

According to Prof Bragg, we are living in a post-antibiotic era. “Although food standards are higher in developed countries such as in Europe – where people can pay more for poultry that were fed diets with reduced antibiotics, it is important to keep in mind that people cannot pay the same for poultry in developing countries. These countries often import poultry from countries where the food standards are not that high and where birds were treated to diets containing more antibiotics. A large supplier of poultry in Africa is small-scale farmers, who also feed their birds food containing higher levels of antibiotics.” 

“We need to look at the antibiotic problem as a global problem; a concern that will be with us for a while,” said Prof Bragg.

One solution provided by the group was for mankind to reduce its meat intake and moving to a more plant-based diet. This will have a significant effect on animal welfare as well as reducing the demand for antibiotics.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept